Sammenligning af Ivonescimab og pembrolizumab ved NSCLC
Dette er en AI opsummering af abstractet til “Comparing the Efficacy and Safety of Ivonescimab with Pembrolizumab in PD-L1-Positive Advanced Non-Small Cell Lung Cancer: HARMONi-2 Phase 3 Trial”. Ivonescimab significantly improved progression-free survival compared with pembrolizumab in untreated patients with advanced PD-L1 positive non-small cell lung cancer. The study was published in The Lancet. HARMONi-2